- Home
- VPV vs CGEN Comparison
VPV vs CGEN Comparison
Compare VPV & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VPV | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.0M | 191.1M |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | VPV | CGEN |
|---|---|---|
| Price | $10.87 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 22.5K | ★ 283.7K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.23 | $1.30 |
| 52 Week High | $11.50 | $3.24 |
Technical Indicators
Market Signals| Indicator | VPV | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 46.78 |
| Support Level | $10.73 | $2.20 |
| Resistance Level | $11.32 | $2.54 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 20.59 | 29.31 |
Price Performance
Historical ComparisonAbout VPV Invesco Pennsylvania Value Municipal Income Trust (DE)
Invesco Pennsylvania Value Municipal Income Trust is a diversified, closed-end management investment company. The investment objective is to provide common shareholders with a high level of current income exempt from federal and Pennsylvania income taxes and, where possible under local law, local income and personal property taxes, consistent with preservation of capital.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.